- BIA IPAC
- Pharmaceuticals/life sciences
- Website: http://www.astx.com
Vice President, IP at Astex Pharmaceuticals
Michelle Jones is a European and chartered UK patent attorney. In 2000, she joined Astex Pharmaceuticals (a wholly owned subsidiary of Otsuka Pharmaceuticals, previously Astex Therapeutics), a leader in fragment-based drug discovery, and was appointed head of intellectual property in 2016.
Handling a global portfolio of pre-clinical, clinical and marketed pharmaceutical compounds, Dr Jones is accomplished in a wide range of areas, including European, US and foreign patent practice, as well as freedom-to-operate and IP licence strategies. As part of the deal team for agreement negotiations, including alliances with major pharmaceutical companies such as MSD, Janssen and Novartis, she has gained significant experience of implementing R&D collaborations, as well as executing IP due diligence activities to support collaboration and licensing initiatives, external fund-raising and investment decisions.
Dr Jones has experience of UK High Court and Court of Appeal litigation (Astex Therapeutics Ltd v AstraZeneca AB  EWCA Civ 2444; Astex Therapeutics Ltd v AstraZeneca AB  EWHC 1442 (Ch); and Astex Therapeutics Ltd v AstraZeneca AB  EWHC 2759 (Ch)). She has also managed trademark protection issues for brand names, house marks and domain names including coexistence agreements.
Dr Jones is vice chair of the BioIndustry Association IP Advisory Committee, a member of the Chartered Institute of Patent Attorneys Life Science Committee and a fellow of the Royal Society of Chemistry. She has a BSc (hons) from the University of Birmingham and a PhD from the University of Cambridge.